LRRFIP1 and glioblastoma: Moreover, miR-21 in glioblastoma cells can target LRRFIP1 and thereby facilitate NFκB pathway activation [41], while silencing miR-21 can strengthen the anti-tumour effects of sunitinib (a tyrosine kinase inhibitor) in U87 human glioblastoma cells [42].